Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.

Nielsen R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M, Stenling A, Mittmann N.

Respir Med. 2013 Nov;107(11):1709-21. doi: 10.1016/j.rmed.2013.06.007. Epub 2013 Jul 13.

2.
3.

A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.

Kern DM, Williams SA, Tunceli O, Wessman C, Zhou S, Pethick N, Elhefni H, Trudo F.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 18;9:775-83. doi: 10.2147/COPD.S64491. eCollection 2014.

4.

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.

Wickstrøm J, Dam N, Malmberg I, Hansen BB, Lange P.

Clin Respir J. 2009 Jul;3(3):169-80. doi: 10.1111/j.1752-699X.2009.00134.x.

PMID:
20298400
5.

An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma.

Jönsson B, Berggren F, Svensson K, O'Byrne PM.

Respir Med. 2004 Nov;98(11):1146-54.

PMID:
15526817
6.

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Review.

PMID:
22972134
7.

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.

Löfdahl CG, Ericsson A, Svensson K, Andreasson E.

Pharmacoeconomics. 2005;23(4):365-75.

PMID:
15853436
8.

Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.

Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF.

Pharmacoeconomics. 2006;24(7):695-708. Erratum in: Pharmacoeconomics. 2008;26(10):894.

PMID:
16802845
9.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.

Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19.

10.

Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.

Vogelmeier C, Naya I, Ekelund J.

Clin Drug Investig. 2012 Jul 1;32(7):439-49. doi: 10.2165/11598840-000000000-00000.

PMID:
22607479
11.
13.

Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.

Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.

J Med Econ. 2011;14(6):769-76. doi: 10.3111/13696998.2011.622817. Epub 2011 Sep 27.

PMID:
21942463
14.

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.

Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 28;10:2055-66. doi: 10.2147/COPD.S90658. eCollection 2015.

15.

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.

Hoogendoorn M, Al MJ, Beeh KM, Bowles D, Graf von der Schulenburg JM, Lungershausen J, Monz BU, Schmidt H, Vogelmeier C, Rutten-van Mölken MP.

Eur Respir J. 2013 Mar;41(3):556-64. doi: 10.1183/09031936.00027212. Epub 2012 Jun 14.

16.

Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.

Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B.

Respir Med. 2014 Dec;108(12):1786-93. doi: 10.1016/j.rmed.2014.09.015. Epub 2014 Oct 2.

PMID:
25307414
17.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M.

Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30.

18.

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.

Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ.

Respir Med. 2012 Feb;106(2):257-68. doi: 10.1016/j.rmed.2011.07.020. Epub 2011 Oct 26.

19.
20.

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM.

Value Health. 2005 Jan-Feb;8(1):32-46.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk